Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114187 | 1.00 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL232806 | 0.84 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5222288 | 0.82 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL903939 | 0.81 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL17643108 | 0.81 | GRIN1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17643355 | 0.81 | GRIN1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2114839 | 0.81 | GRIN1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2114840 | 0.81 | GRIN1 (0.44) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24136460 | 0.81 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20086419 | 0.81 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430006-B1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8697883-B2 | Cyclopenta[C]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | EPOR, ACAD9, CBR1 | SLC6A4 3490/4885SLC6A2 1817/4885SLC6A3 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.